Surprising
Vitamin E improved liver histology in 29% of MASH patients — but serious adverse events also occurred in the same trial
This is among the first rigorous trials on vitamin E for MASH, so the finding is promising but far from settled — especially given the serious adverse events reported and the fact that it only tested a specific Chinese clinical population.
MASH is a fatty liver disease with inflammation that can progress to cirrhosis. In this randomized trial, 300 mg/day of vitamin E led to measurable improvements in liver tissue for about 29% of patients, compared to 14% on placebo. However, serious side effects were reported in the vitamin E group, and because this is one of the first studies on this combination, the results need replication before drawing broad conclusions.
Where this fits in the evidence
This is among the first studies we've indexed on Vitamin E for Improved Hepatic Histology — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- 2025-02
- Cell reports. Medicine
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.